Table 2. Association between CDK4/6SA and various clinicopathological backgrounds, including Ki-67 expression.
| CDK4/6SA | ||||
|---|---|---|---|---|
| Parameter | Criteria | ⩽4.8 | >4.8 | P-value |
| Age | <60 | 35 | 33 | 0.845 |
| ⩾60 | 20 | 21 | ||
| Stage | ⩽II | 36 | 41 | 0.293 |
| ⩾III | 19 | 13 | ||
| Lymph-node metastasis | No | 44 | 44 | 0.760 |
| Yes | 7 | 5 | ||
| Histological grade | I | 34 | 41 | 0.140 |
| II&III | 20 | 12 | ||
| Tumour size | <5 cm | 30 | 30 | 1.000 |
| ⩾5 cm | 22 | 23 | ||
| Myometrial invasion | ⩽1/2 | 44 | 43 | 0.798 |
| >1/2 | 10 | 8 | ||
| Vascular invasion | No | 41 | 44 | 0.474 |
| Yes | 13 | 9 | ||
| Lymphatic invasion | No | 40 | 44 | 0.347 |
| Yes | 14 | 9 | ||
| CDK4 IHC average score | <1.0 | 25 | 25 | 0.928 |
| ⩾1.0 | 28 | 25 | ||
| Ki-67 IHC average score | <1.5 | 12 | 22 | 0.035 |
| ⩾1.5 | 41 | 28 | ||
Abbreviations: CDK4=cyclin-dependent kinase 4; CDK4/6SA=CDK4/6-specific activity; IHC=immunohistochemistry.Bold entries denote P<0.05 (significant).